Q BioMed Inc (OTCQB:QBIO) Chief Commercial Officer Kristin Keller tells Proactive the New York-based group has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the company’s metastatic bone pain drug Strontium89.
Keller says Clionix has received “exclusive rights” to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait and Pakistan.